一分钟看懂
这是一项关于Pancreatic Ductal Adenocarcinoma的不适用研究，登记的药物或干预包括Prehabilitation program，当前状态为招募中。登记地点显示中国Dijon、Grenoble、Lille、Marseille等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Prehabilitation program · 不适用
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Centre Hospitalier Universitaire Dijon Bourgogne · Dijon
- Institut Daniel Hollard - Groupe Hospitalier Mutualiste de Grenoble · Grenoble
- Centre Hospitalier Universitaire de Lille · Lille
- Hospital La Timone · Marseille
- Institut Paoli-Calmettes · Marseille
- CHU de Reims · Reims
- CENTRE HOSPITALIER UNIVERSITAIRE ROUEN - CHU Charles Nicolle · Rouen
- INSTITUT CURIE de SAint Cloud · Saint-Cloud
- Institut de Cancerologie de L'Ouest Rene Gauducheau · Saint-Herblain
- Groupe hospitalier Rance Emeraude (CHU Saint-Malo) · St-Malo
- Centre Hospitalier Universitaire Tours - Hopital Trousseau · Tours
公开的入选条件
- 1. Signed and dated patient informed consent form (ICF) and willingness to comply with all study procedures and availability for the study duration,
- 2. Histologically or cytologically proven, localized PDAC or OGC,
- 3. Indication to a neoadjuvant treatment with triplet chemotherapy for ≥ 4 cycles (8 weeks) validated by the multidisciplinary board, Note: Patient treated for PDAC, dose reduction of oxaliplatin or irinotecan is authorized.
- 4. Age \> 18 years; If aged ≥ 75 years: G8 score must be ≥ 14 and if \< 14 validation of oncogeriatric specialist,
- 5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 at the inclusion visit,
- 6. No prior treatment for PDAC or OGC before starting chemotherapy (FLOT or FOLFIRINOX),
- 7. At least one measurable or evaluable lesion as assessed by Computerized Tomography scan or Magnetic resonance imaging according to RECIST 1.1 and feasibility of repeated radiological assessments,
- 8. Adequate hematologic and end-organ function allowing the triple combination chemotherapy protocol,
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06275737；登记信息更新于 2026-09-17。